The Ten Bagger Quest - another string to Angle’s bow
Significant progress with prostate cancer
By Michael Crockett
There was exciting news from Angle today. Bart’s Cancer Institute has provided evidence in support of Angle’s Parsortix system being used for the detection and assessment of prostate cancer.
Angle has gained many supporters from key cancer specialists worldwide in recent months. Its liquid biopsy technology has been shown to be effective with a number of cancers. A clinical trial is already ongoing to assess Parsortix’s effectiveness on Ovarian cancer and today’s news could lead to a very large clinical application with prostate cancer, the second most common cancer in men worldwide.
The Ten Bagger Quest
A number of the companies featured in AimZine’s Ten Bagger Quest articles are now making excellent progress; most notably Surface Transforms and Software Radio Technology. We have recently identified some further small companies which have exciting ten bagger potential and will be publishing further AimZine Ten Bagger articles in the near future.
Angle (AIM: AGL)
http://www.angleplc.com/
Introduction
Investor’s Champion highlighted the potential of Angle in this July 2013 AimZine Ten Bagger Quest article.
Since that time Angle has made considerable progress in trials with a number of collaborators - see the impressive list at http://www.angleplc.com/the-company/collaborators/.
Angle’s Parsortix system has already been demonstrated with ovarian, prostate, breast, lung, colorectal, pancreatic and renal cancers. To date…
